| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||
|
lowchia
Veteran |
14-Jan-2011 23:49
|
||
|
x 0
x 0 Alert Admin |
On Friday, Biosensors re-tests its support at $1.11 and closed at $1.14 with HIGH volume of 13.16 million shares traded. A white candle sticks with long lower shadow similar to “hammer” demonstrate the strength of the key support at $1.11. RSI & MACD are flat as RSI trend sideway. Important Resistance of Biosensors: $1.15 Immediate Support of Biosensors: $1.11 Currently prices are resisted by the 20 days MA at $1.15 Biosensors have re-tested the critical support at $1.11 today and rebound strongly forming a candle stick with long lower shadow to indicate the strength of the support. $1.11 support is expected to be very strong and...............READ MORE |
||
| Useful To Me Not Useful To Me | |||
|
james87
Veteran |
14-Jan-2011 23:29
|
||
|
x 0
x 0 Alert Admin |
Nice. Finally there is something to push this counter..
|
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
allright
Senior |
14-Jan-2011 23:17
|
||
|
x 0
x 0 Alert Admin |
BIOSENSORS INTERNATIONAL GROUP, LTD. (Incorporated in Bermuda) (Company Registration Number: EC 24983) DATE OF ANNOUNCEMENT OF FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL YEAR 2011 ENDED 31 DECEMBER 2010 Biosensors International Group, Ltd. (“Biosensors” or the “Company”) will announce its financial results for the third quarter of its fiscal year 2011, ended 31 December 2010 on 28 January 2011, after trading hours. Dr. Jack Wang, Co-CEO and Acting CFO, and Mr. Jeffrey Jump, Co-CEO will host an analyst briefing teleconference on that day at 5.30 pm (Singapore time) to discuss the financial results and provide an update on the Company’s progress. A live audio-cast of the briefing will be available to all interested parties at Biosensors’ corporate website at www.biosensors.com. By Order of the Board Yoh-Chie Lu Chairman 14 January 2011
|
||
| Useful To Me Not Useful To Me | |||
|
chriscyng
Member |
14-Jan-2011 13:00
|
||
|
x 0
x 0 Alert Admin |
Can 1.11 & 1.10 hold? it may be just another fake Q. | ||
| Useful To Me Not Useful To Me | |||
|
topdog22
Senior |
14-Jan-2011 07:31
|
||
|
x 0
x 0 Alert Admin |
Understand BIG presented last evening and hosted a dinner any feedback? take aways? |
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
ccoolidge
Member |
13-Jan-2011 14:27
|
||
|
x 0
x 0 Alert Admin |
My personal opinion is checking the individual patents by BIG and ABT is somewhat barking up the wrong tree. Patents are not the most important "defense" against by rival pharmaceutical companies. It is clinical evidence, backed up by properly conducted large scale, long term Phase-III clinical trials. These cannot be replicated overnight, even if ABT has a far more superior product. In the short and medium term, I find BIG's clinical data is much more robust than its immediate competitors. Slowly but surely, this distinct competitive advantage may be threatened when fresh clinical data from newly conducted trials prove who is the real winner after all. I would also watch out for the other clinical trials by BIG which track the number of "adverse events". |
||
| Useful To Me Not Useful To Me | |||
|
metaphoricsymbol
Member |
13-Jan-2011 09:54
|
||
|
x 0
x 0 Alert Admin |
AsianPCR starts today in SIngapore. Will discuss value of reabsorbable stent and degradable polymers. |
||
| Useful To Me Not Useful To Me | |||
|
topdog22
Senior |
13-Jan-2011 08:44
|
||
|
x 0
x 0 Alert Admin |
Thankyou for your thoroughness. But, didn't BIG file a patent application for a totally biodegradable PLA stent with Biolimus? Also did they try to get a claim for all Limus based substances on that patent? | ||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
tbt001
Member |
12-Jan-2011 08:07
|
||
|
x 0
x 0 Alert Admin |
I have read throught the "Claims" section of BIG's patent 6939376. It looks that ABT's stent does not violate this. Don't know if BIG have other patents that covers this but I would think that a big company like ABT have done their homework. |
||
| Useful To Me Not Useful To Me | |||
|
topdog22
Senior |
12-Jan-2011 06:27
|
||
|
x 0
x 0 Alert Admin |
Just checked US markets are up BUT ABT is down again today. I guess no one seems to think their new stent will generate any significant income or market share in the forseeable future. Don't see this impacting BIG any time soon. Also, depending on how broad issued patent is BIG may have viable claim. |
||
| Useful To Me Not Useful To Me | |||
|
tbt001
Member |
11-Jan-2011 14:20
|
||
|
x 0
x 0 Alert Admin |
Re: Abbott's new Absorb stent - fully bio-absorbable including the scaffold Trial results are not sufficient to show efficacy
(low N; and less than 3 years?). Would you use this if you need a
stent??? If I need one I would certainly ask for BioMatrix, or perhaps
BioFreedom; atleast for now. Not expected to launch till end 2012 in Europe and not expected to get US FDA approval till 2015. Planning a N=1000 trial with 500 in Europe. Unlikely to violate Biosensor's patent no: 6939376. Also, they have yet to show that Absorb is better in an all comers trial. Take note their trials are "non-randomized". Probably not a concern to Biosensors in the short
term but could pose to be significant competition in the long term; if
they can show superior efficacy. Abbott's current stent Xience is already doing very well with a significant market share. |
||
| Useful To Me Not Useful To Me | |||
|
novicealex
Member |
11-Jan-2011 11:35
|
||
|
x 0
x 0 Alert Admin |
Cut loss at 1.15 :( Need to make back from others now.. I will be back again. |
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
investor
Senior |
11-Jan-2011 11:02
|
||
|
x 0
x 0 Alert Admin |
Agree - I don't think that the product will gain significant mkt share. The product will probably be for short simple lesions, and in veiw of the fact that it takes 2 years for the polymer to be eroded completely (polymer stent structure, not the polymer coating), it will not be suitable for people who do not want to be on DAPT for too long. Furthermore, too long an exposure to DAPT, also causes bleeding issues, which my lead to higher mortality. The actual 'real world' patients have long complicated lesions, and without a permanent scafolding (ie metallic stent), the vessel may 'collapse'. Not a call to buy/sell. |
||
| Useful To Me Not Useful To Me | |||
|
topdog22
Senior |
11-Jan-2011 07:02
|
||
|
x 0
x 0 Alert Admin |
Apparently, th CE approval on Abbot's biodegradable stent NOT considered significant by investors in the US. Abbot fell US $0.50. Please keep in mind that CE is more concerned with device safety, i.e. will this device cause harm: as opposed to efficacy; does this device deliver superior results which will take many years of large clinical trials to prove. Abbott to launch first absorbable stent in EuropeEuropean regulators OK Abbott Labs' first-of-a-kind absorbable stent
Abbott to launch first absorbable stent in Europe European regulators OK Abbott Labs' first-of-a-kind absorbable stent Share retweet EmailPrint..Companies:Abbott Laboratories Common StocJohnson & Johnson Common StockMedtronic Inc. Common Stock.Related Quotes Symbol Price Change ABT 47.94 -0.43 JNJ 62.16 -0.44 MDT 36.50 +0.09 {"s" : "abt,jnj,mdt","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} On Monday January 10, 2011, 4:39 pm EST WASHINGTON (AP) -- Drug and medical device company Abbott Laboratories said Monday it received European approval to market a first-of-a-kind stent that absorbs into the body within two years of implantation. Stents are mesh-metal tubes used to prop open arteries after they have been cleared of potentially deadly fat deposits. A long-standing concern with the implants is the risk for blood clots caused by scar tissue growing over the metal stent. Abbott's Absorb stent is the first in a new class of devices designed to address the problem by breaking down inside the body. The stent is made from polylactide, a biodegradable material used in absorbable surgical sutures. North Chicago-based Abbott said it would make the stent available at certain European hospitals this year, with a full roll-out planned for late-2012. Abbott said it will continue studying the stent in coming years and plans to enroll 1,000 patients with various types of blockages. The company expects to submit the device for U.S. approval in 2015, according to a company spokesman. Abbott already leads the U.S. market for stents with its Xience V drug-coated stent. The drug coatings are designed to prevent scar tissue from growing back through the mesh and reclogging the patient's artery. The company's stents posted global sales of $505 million in the last quarter. Similar products are marketed by Johnson & Johnson, Medtronic Inc. and Boston Scientific. Shares of Abbott Laboratories fell 50 cents to $47.87 |
||
| Useful To Me Not Useful To Me | |||
|
investor
Senior |
10-Jan-2011 22:59
|
||
|
x 0
x 0 Alert Admin |
Abbot has just announced that they got the CE mark approval for the bio-absorbable DES. (See www.pcronline.com). There were 2 clinical trials conducted for the DES, first one with 30 patients followed upto 4 yrs, and the 2nd one (with improved stent design) of 101 patients, followed upto 9 mths, making a total of ONLY 131 patients. Now, who says that you cannot get CE mark, based on just a few hundred patients ? It is quite a surprise to see Abbot get the CE mark so early as they seem to be making adjustments to the stent design in the 2nd trial. That might account for the knee-jerk reaction to Biosensor's share price today. The really important question in this issue - IS the Abbot bio-absorbable DES which uses a PLA polymer as the stent, as well as uses the PLA polymer to elute the Everolimus drug, violating one of Biosensor's patent US patent no 6939376 ?. The patent announcement by Biosensors is attached below for info : Singapore, 19 September 2005 – today announced that on September 6, 2005 it was granted a patent from the United States Patent and Trademark Office covering the technology behind its drug-eluting stents (“DES”). Specifically, this U.S. patent, (Patent Number 6939376) covers the use of anti-restenotic, immuno-suppressive drugs including Everolimus, in combination with a biodegradable drug release polymer coating on an endovascular stent. The patent was filed in April 2002, and is valid in the U.S. for 20 years from the filing date. The Company has also filed for the same patent in Australia, Japan, Europe, which it is anticipating to receive. This issue is too complicated for me to comment. Anyone, any ideas ? For info. Not a call to buy/sell. Biosensors International Group, Ltd. (Bloomberg: BIG SP), |
||
| Useful To Me Not Useful To Me | |||
|
metaphoricsymbol
Member |
10-Jan-2011 09:30
|
||
|
x 0
x 0 Alert Admin |
Japan's MHLW or PMDA has not released January 2011 list of newly approved drug or medical devices Last week they announced plan to reduce manpower by 1000, but not list of medical devices yet. Will have to watch for this Friday or next- as their usual daye of announcement is Friday. |
||
| Useful To Me Not Useful To Me | |||
|
topdog22
Senior |
10-Jan-2011 07:45
|
||
|
x 0
x 0 Alert Admin |
Are the MOH Approvals known? Did Terumo gain approval? |
||
| Useful To Me Not Useful To Me | |||
|
bishan22
Elite |
07-Jan-2011 16:04
|
||
|
x 0
x 0 Alert Admin |
Strong support at 1.16. Q whole morning still cannot get. 
|
||
| Useful To Me Not Useful To Me | |||
|
metaphoricsymbol
Member |
06-Jan-2011 16:51
|
||
|
x 0
x 0 Alert Admin |
Will likely test 1.20 resistance tomorrow. Will Japan MHLW include Nobori in their January 2011 list of newly approved Pharmeceutical and Medical devices at end of tomorrow? If so can see price price go past recent high of 1.26 to 1.30-1.32 next week. But if by Monday no announcement from Terumo or Biosensors, meaning approval delayed again to Feb 4 list, could see pull back again to 1.12-1.15 range for a shortwhile. Unlikely to fall below 1.10 in the light of coming result at end Jan or early Feb where earnings expected to see significant jump. |
||
| Useful To Me Not Useful To Me | |||
|
xanovax
Member |
06-Jan-2011 15:43
|
||
|
x 0
x 0 Alert Admin |
Target price? I see more analysts upgrading the target price soon :) |
||
| Useful To Me Not Useful To Me | |||